Tumour Ablation Devices Market

Tumour Ablation Devices Market Size, Market Forecast and Outlook By FMI

The tumour ablation devices market was valued at USD 2.2 billion in 2025. The market is set to reach USD 2.5 billion by 2026-end and grow at a CAGR of 13.8% between 2026–2036 to reach USD 9.1 billion by 2036. Radiofrequency ablation will dominate with a 39.7% share, while Liver Cancer will lead with a 28.5%% share.

Summary of the Tumour Ablation Devices Market

• Demand and Growth Drivers
  • Rising cancer incidence and minimally invasive treatment preference are likely to support demand through the forecast period.
  • Reimbursement expansion and combination therapy protocols are expected to remain consistent growth drivers from 2026 to 2036.
  • Emerging market oncology investment and new clinical indications are expected to create additional opportunities.
• Product and Segment View
  • Radiofrequency ablation is likely to remain the leading product type segment, accounting for 39.7% of demand in 2026.
  • Liver Cancer is expected to account for 28.5% of the application type category.
  • Growth across segments is expected to remain uneven, with higher-specification categories outpacing standard alternatives.
• Geography and Competitive Outlook
  • China is likely to lead growth at 18.6% CAGR.
  • India at 17.3% CAGR represents the second-fastest growth corridor.
  • Companies that combine product breadth with distribution reach and service capability are likely to strengthen competitive positioning.
• Analyst Opinion
  • The tumour ablation devices market is evolving toward multi-modality platforms and expanded clinical indications driven by clinical evidence. Companies that invest in clinical evidence generation, new indications, and emerging market distribution are better positioned. The market is expected to create USD 6.62 billion in incremental opportunity between 2026 and 2036.
  • Growth is concentrated in regions where cancer incidence and healthcare infrastructure are expanding.
  • Adoption is increasing due to rising cancer incidence, expanding clinical adoption of minimally invasive treatment approaches, and favorable reimbursement for ablation procedures.
  • The strongest growth is expected from China and India.

Key Takeaways, Market Size, and Forecast

• The tumour ablation devices market was valued at USD 2.20 billion in 2025.
• By 2036, the Tumour Ablation Devices Market is expected to be worth USD 9.12 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 13.8%.
• The market is projected to create an incremental opportunity of USD 6.62 billion between 2026 and 2036.
• In 2026, Radiofrequency ablation is expected to account for 39.7% of the product type, driven by rising cancer incidence, expanding clinical adoption of minimally invasive treatment approaches, and favorable reimbursement for ablation procedures.
• China (18.6%) and India (17.3%) are two of the fastest growing markets in the world.

Tumour Ablation Devices Market Definition

The tumour ablation devices market encompasses all commercially traded products, solutions, and services categorized by product type, application type, end use type. Revenue from sales across North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa during 2026 to 2036.

Tumour Ablation Devices Market Inclusions

• Market scope includes all tumour ablation devices products sold commercially, covering Radiofrequency ablation, Laser ablation, High intensity focused ultrasound ablation, Microwave ablation, Cryo ablation; Liver Cancer, Kidney Cancer, Colorectal Cancer, Bone Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Other Cancers; Hospitals, 500 and more beds hospitals, 200 to 499 beds hospitals, Less than 200 beds hospitals, Ambulatory Surgical Centers. Revenue tracked from 2026 to 2036.

Tumour Ablation Devices Market Exclusions

• The scope excludes non-commercial transactions, internal transfers, and prototype products. Government-funded research without commercial procurement is also excluded.

Tumour Ablation Devices Market Research Methodology

• Primary Research: Interviews with manufacturers, distributors, and end-user procurement teams across key markets.
• Desk Research: Analysis of industry data, trade statistics, and regulatory filings.
• Market Sizing and Forecasting: Bottom-up aggregation of procedural volumes, device shipment data, and clinical adoption rates, with regional curves and top-down validation.
• Data Validation: Cross-checked quarterly against production statistics and manufacturer disclosures.

Why is the Tumour Ablation Devices Market Growing?

• Rising cancer incidence, expanding clinical adoption of minimally invasive treatment approaches, and favorable reimbursement for ablation procedures are supporting a CAGR of 13.8% through 2036.
• China leads growth at 18.6%.
• Radiofrequency ablation accounts for 39.7% of the product type segment.

Global cancer incidence is increasing due to aging populations, lifestyle factors, and improved diagnostic detection. The growing patient population eligible for ablation procedures directly expands market demand. Ablation is indicated for patients who are not suitable for surgical resection or who prefer minimally invasive treatment. The expanding clinical evidence base for ablation across tumor types is broadening the addressable patient population beyond liver cancer to kidney, lung, bone, and soft tissue applications.

Clinical and patient preference for minimally invasive treatment approaches is shifting the treatment mix toward ablation and away from open surgical procedures in appropriate clinical settings. Ablation offers shorter recovery times, reduced complications, and outpatient procedural capability. The shift toward minimally invasive approaches is supported by clinical evidence demonstrating comparable outcomes to surgery in selected patient populations. This preference trend provides structural growth support for ablation device demand.

Radiofrequency ablation maintains the largest technology share due to established clinical evidence, physician familiarity, and procedural versatility. The technology is well-characterized across multiple tumor types and clinical settings. Alternative technologies including microwave, cryoablation, and irreversible electroporation compete in specific clinical niches. RF ablation manufacturers benefit from installed base advantages and established reimbursement pathways.

Market Segmentation Analysis

• The tumour ablation devices market is segmented by product type, application type, end use type.
• Radiofrequency ablation maintains the largest share at 39.7% in 2026.
• Liver Cancer accounts for 28.5% of the application type category.

Insights into the Radiofrequency ablation Segment

• Radiofrequency ablation accounts for 39.7% of the product type segment in 2026. Demand reflects established clinical evidence and physician familiarity with thermal ablation. Growth is expected to remain consistent through the forecast period.

Insights into the Liver Cancer Segment

• Liver Cancer accounts for 28.5% of the application type segment in 2026. Demand reflects the concentration of ablation procedures in liver cancer, the most established clinical indication. Growth is expected to remain consistent through the forecast period.

Tumour Ablation Devices Market Drivers, Restraints, and Opportunities

• Cancer incidence and minimally invasive preference are creating structured demand.
• Reimbursement variability and procedural training requirements remain the primary restraints.
• New indications and combination therapies represent the most significant opportunities.

The tumour ablation devices market continues to expand as rising cancer incidence, expanding clinical adoption of minimally invasive treatment approaches, and favorable reimbursement for ablation procedures create sustained demand.

Rising Cancer Incidence Expands Procedural Demand

• Global cancer incidence is increasing due to aging populations, lifestyle factors, and improved diagnostic detection. The growing patient population eligible for ablation procedures directly expands market demand. Ablation is indicated for patients who are not suitable for surgical resection or who prefer minimally invasive treatment. The expanding clinical evidence base for ablation across tumor types is broadening the addressable patient population beyond liver cancer to kidney, lung, bone, and soft tissue applications.

Minimally Invasive Preference Shifts Treatment Mix

• Clinical and patient preference for minimally invasive treatment approaches is shifting the treatment mix toward ablation and away from open surgical procedures in appropriate clinical settings. Ablation offers shorter recovery times, reduced complications, and outpatient procedural capability. The shift toward minimally invasive approaches is supported by clinical evidence demonstrating comparable outcomes to surgery in selected patient populations. This preference trend provides structural growth support for ablation device demand.

Radiofrequency Ablation Maintains Technology Leadership

• Radiofrequency ablation maintains the largest technology share due to established clinical evidence, physician familiarity, and procedural versatility. The technology is well-characterized across multiple tumor types and clinical settings. Alternative technologies including microwave, cryoablation, and irreversible electroporation compete in specific clinical niches. RF ablation manufacturers benefit from installed base advantages and established reimbursement pathways.

Reimbursement Expansion Supports Adoption Growth

• Favorable reimbursement decisions for ablation procedures are supporting adoption growth across healthcare systems. Coverage expansion for additional tumor types and clinical indications broadens the economically viable patient population. Reimbursement rates that adequately compensate for procedure costs, physician time, and device expenses are essential for sustainable adoption. Companies that invest in health economics evidence and payer engagement accelerate reimbursement expansion.

Analysis of Tumour Ablation Devices Market By Key Countries

Country	CAGR
China	18.6%
India	17.3%
Germany	15.9%
France	14.5%
UK	13.1%
USA	11.7%
Brazil	10.4%

• China leads at 18.6% CAGR.
• India at 17.3% represents the second-fastest growth corridor.
• Germany (15.9%) and France (14.5%) show sustained growth.

The global tumour ablation devices market is expected to expand at a CAGR of 13.8% from 2026 to 2036.

Demand Outlook for Tumour Ablation Devices Market in China

• China is projected to register a CAGR of 18.6% through 2036. Growth reflects rising cancer incidence, expanding interventional oncology capabilities, and increasing clinical adoption of minimally invasive ablation procedures.
• Rising cancer prevalence is increasing the patient population eligible for ablation procedures.
• Hospital investment in interventional oncology is expanding procedural access.
• Favorable reimbursement decisions are supporting adoption of ablation as a treatment modality.

Future Outlook for Tumour Ablation Devices Market in India

• India is projected to register a CAGR of 17.3% through 2036. Growth reflects rising cancer incidence, expanding interventional oncology capabilities, and increasing clinical adoption of minimally invasive ablation procedures.
• Rising cancer prevalence is increasing the patient population eligible for ablation procedures.
• Hospital investment in interventional oncology is expanding procedural access.
• Favorable reimbursement decisions are supporting adoption of ablation as a treatment modality.

Opportunity Analysis of Tumour Ablation Devices Market in Germany

• Germany is projected to register a CAGR of 15.9% through 2036. Growth reflects rising cancer incidence, expanding interventional oncology capabilities, and increasing clinical adoption of minimally invasive ablation procedures.
• Rising cancer prevalence is increasing the patient population eligible for ablation procedures.
• Hospital investment in interventional oncology is expanding procedural access.
• Favorable reimbursement decisions are supporting adoption of ablation as a treatment modality.

In-depth Analysis of Tumour Ablation Devices Market in France

• France is projected to register a CAGR of 14.5% through 2036. Growth reflects rising cancer incidence, expanding interventional oncology capabilities, and increasing clinical adoption of minimally invasive ablation procedures.
• Rising cancer prevalence is increasing the patient population eligible for ablation procedures.
• Hospital investment in interventional oncology is expanding procedural access.
• Favorable reimbursement decisions are supporting adoption of ablation as a treatment modality.

Sales Analysis of Tumour Ablation Devices Market in UK

• UK is projected to register a CAGR of 13.1% through 2036. Growth reflects rising cancer incidence, expanding interventional oncology capabilities, and increasing clinical adoption of minimally invasive ablation procedures.
• Rising cancer prevalence is increasing the patient population eligible for ablation procedures.
• Hospital investment in interventional oncology is expanding procedural access.
• Favorable reimbursement decisions are supporting adoption of ablation as a treatment modality.

Growth Analysis of Tumour Ablation Devices Market in USA

• USA is projected to register a CAGR of 11.7% through 2036. Growth reflects rising cancer incidence, expanding interventional oncology capabilities, and increasing clinical adoption of minimally invasive ablation procedures.
• Rising cancer prevalence is increasing the patient population eligible for ablation procedures.
• Hospital investment in interventional oncology is expanding procedural access.
• Favorable reimbursement decisions are supporting adoption of ablation as a treatment modality.

Competitive Landscape and Strategic Positioning

• Medtronic plc. maintains a strong position.
• Boston Scientific Corporation and Johnson & Johnson Service Inc. (Ethicon, Inc.) compete through specialized capabilities.
• New entrants target underserved segments and emerging markets.
• The competitive landscape reflects a mix of global and regional players.
• Medtronic plc. leads through established infrastructure and multi-regional capabilities.
• Barriers include capital requirements, certifications, and established customer relationships.

Key Companies in the Tumour Ablation Devices Market

Key global companies include:

• Medtronic plc., Boston Scientific Corporation, Johnson & Johnson Service Inc. (Ethicon, Inc.), AngioDynamics maintain strong positions.
• Bioventus Inc. (Misonix Inc.), EDAP TMS, Chongqing Haifu Medical Technology Co., Ltd hold regional positions.
• Mermaid Medical are emerging participants.

Competitive Benchmarking: Tumour Ablation Devices Market

Company	Product Portfolio	Clinical Evidence	Hospital Access	Geographic Reach
Medtronic plc.	High	High	Strong	Global
Boston Scientific Corporation	High	High	Strong	Global
Johnson & Johnson Service Inc. (Ethicon, Inc.)	High	Medium	Strong	Global
AngioDynamics	Medium	Medium	Moderate	Global
Bioventus Inc. (Misonix Inc.)	Medium	Medium	Moderate	Regional
EDAP TMS	Medium	Low	Moderate	Regional
Chongqing Haifu Medical Technology Co., Ltd	Low	Low	Moderate	Regional
Mermaid Medical	Low	Low	Limited	Niche

Source: Future Market Insights competitive analysis, 2026.

Key Players in the Tumour Ablation Devices Market

Major Global Players

• Medtronic plc.
• Boston Scientific Corporation
• Johnson & Johnson Service Inc. (Ethicon, Inc.)
• AngioDynamics
• Bioventus Inc. (Misonix Inc.)
• EDAP TMS
• Chongqing Haifu Medical Technology Co., Ltd

Emerging Players/Startups

• Mermaid Medical

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 2.50 Billion to USD 9.12 Billion, at a CAGR of 13.8%
Market Definition	The tumour ablation devices market encompasses products and services across product type, application type, end use type.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	China, India, Germany, France, UK, USA, Brazil, 30 plus countries
Key Companies Profiled	Medtronic plc., Boston Scientific Corporation, Johnson & Johnson Service Inc. (Ethicon, Inc.), AngioDynamics, Bioventus Inc. (Misonix Inc.), EDAP TMS, Chongqing Haifu Medical Technology Co., Ltd, Mermaid Medical
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data.

Segmentation

Tumour Ablation Devices Market Segmented by Product Type:

• Radiofrequency ablation
• Laser ablation
• High intensity focused ultrasound ablation
• Microwave ablation
• Cryo ablation

Tumour Ablation Devices Market Segmented by Application Type:

• Liver Cancer
• Kidney Cancer
• Colorectal Cancer
• Bone Cancer
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Other Cancers

Tumour Ablation Devices Market Segmented by End Use Type:

• Hospitals
• 500 and more beds hospitals
• 200 to 499 beds hospitals
• Less than 200 beds hospitals
• Ambulatory Surgical Centers

Tumour Ablation Devices Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• World Health Organization. (2025). WHO Global Cancer Statistics. WHO.
• USA Food and Drug Administration. (2025). FDA Medical Device Approvals Database. FDA.
• European Commission. (2025). EU Medical Device Regulation Implementation. EC.
• Organisation for Economic Co-operation and Development. (2025). OECD Health Statistics. OECD.
• International Agency for Research on Cancer. (2025). IARC Global Cancer Observatory. IARC.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list.

This Report Answers

• Estimating the size of the tumour ablation devices market and revenue potential from 2026 to 2036.
• Segmentation by product type, application type, end use type.
• Regional insights across more than 30 markets.
• Competitive landscape assessment and company benchmarking.
• Identification of investment opportunities across product segments and geographic markets.
• Supply chain and distribution channel tracking.
• Delivery of data in PDF and Excel formats.